205 related articles for article (PubMed ID: 28428270)
21. Report of a Chinese Cohort with Activated Phosphoinositide 3-Kinase δ Syndrome.
Wang Y; Wang W; Liu L; Hou J; Ying W; Hui X; Zhou Q; Liu D; Yao H; Sun J; Wang X
J Clin Immunol; 2018 Nov; 38(8):854-863. PubMed ID: 30499059
[TBL] [Abstract][Full Text] [Related]
22. A novel monoallelic gain of function mutation in p110δ causing atypical activated phosphoinositide 3-kinase δ syndrome (APDS-1).
Lougaris V; Baronio M; Moratto D; Tampella G; Gazzurelli L; Facchetti M; Martire B; Cardinale F; Lanzarotto F; Bondioni MP; Villanacci V; Grimbacher B; Plebani A
Clin Immunol; 2019 Mar; 200():31-34. PubMed ID: 30639166
[TBL] [Abstract][Full Text] [Related]
23. Activating PI3Kδ mutations in a cohort of 669 patients with primary immunodeficiency.
Elgizouli M; Lowe DM; Speckmann C; Schubert D; Hülsdünker J; Eskandarian Z; Dudek A; Schmitt-Graeff A; Wanders J; Jørgensen SF; Fevang B; Salzer U; Nieters A; Burns S; Grimbacher B
Clin Exp Immunol; 2016 Feb; 183(2):221-9. PubMed ID: 26437962
[TBL] [Abstract][Full Text] [Related]
24. Genetic Defects in Phosphoinositide 3-Kinase δ Influence CD8
Cannons JL; Preite S; Kapnick SM; Uzel G; Schwartzberg PL
Front Immunol; 2018; 9():1758. PubMed ID: 30116245
[TBL] [Abstract][Full Text] [Related]
25. Activated PI3Kδ syndrome type 2: Two patients, a novel mutation, and review of the literature.
Olbrich P; Lorenz M; Cura Daball P; Lucena JM; Rensing-Ehl A; Sanchez B; Führer M; Camacho-Lovillo M; Melon M; Schwarz K; Neth O; Speckmann C
Pediatr Allergy Immunol; 2016 Sep; 27(6):640-4. PubMed ID: 27116393
[TBL] [Abstract][Full Text] [Related]
26. Gain of Function Mutations of PIK3CD as a Cause of Primary Sclerosing Cholangitis.
Hartman HN; Niemela J; Hintermeyer MK; Garofalo M; Stoddard J; Verbsky JW; Rosenzweig SD; Routes JM
J Clin Immunol; 2015 Jan; 35(1):11-4. PubMed ID: 25352054
[TBL] [Abstract][Full Text] [Related]
27. Successful bone marrow transplantation in two sisters with activated phosphoinositide 3-kinase δ syndrome 2.
Sugiyama M; Iguchi A; Yamada M; Terashita Y; Ohshima J; Cho Y; Miyake N; Matsumoto N; Ueki M; Yamazaki Y; Takezaki S; Kobayashi I; Ariga T
Bone Marrow Transplant; 2017 Dec; 52(12):1678-1680. PubMed ID: 28869616
[No Abstract] [Full Text] [Related]
28. Hyper-activated PI3K-δ in immunodeficiency.
Heurtier L; Deau MC; Kracker S
Oncotarget; 2015 Jul; 6(21):18242-3. PubMed ID: 26286043
[No Abstract] [Full Text] [Related]
29. PIK3R1 Mutation Associated with Hyper IgM (APDS2 Syndrome): A Case Report and Review of the Literature.
Yazdani R; Hamidi Z; Babaha F; Azizi G; Fekrvand S; Abolhassani H; Aghamohammadi A
Endocr Metab Immune Disord Drug Targets; 2019; 19(7):941-958. PubMed ID: 30799802
[TBL] [Abstract][Full Text] [Related]
30. Activated PI3K-delta syndrome in an Egyptian pediatric cohort with primary immune deficiency.
Ahmed AA; El Shahaway AA; Hussien SA
Allergol Immunopathol (Madr); 2020; 48(6):686-693. PubMed ID: 32349894
[TBL] [Abstract][Full Text] [Related]
31. Occurrence of B-cell lymphomas in patients with activated phosphoinositide 3-kinase δ syndrome.
Kracker S; Curtis J; Ibrahim MA; Sediva A; Salisbury J; Campr V; Debré M; Edgar JD; Imai K; Picard C; Casanova JL; Fischer A; Nejentsev S; Durandy A
J Allergy Clin Immunol; 2014 Jul; 134(1):233-6. PubMed ID: 24698326
[No Abstract] [Full Text] [Related]
32. Clinical Challenges: Identification of Patients With Novel Primary Immunodeficiency Syndromes.
Buchbinder D; Seppanen M; Rao VK; Uzel G; Nugent D
J Pediatr Hematol Oncol; 2018 Jul; 40(5):e319-e322. PubMed ID: 29200144
[TBL] [Abstract][Full Text] [Related]
33. Human PIK3R1 mutations disrupt lymphocyte differentiation to cause activated PI3Kδ syndrome 2.
Nguyen T; Lau A; Bier J; Cooke KC; Lenthall H; Ruiz-Diaz S; Avery DT; Brigden H; Zahra D; Sewell WA; Droney L; Okada S; Asano T; Abolhassani H; Chavoshzadeh Z; Abraham RS; Rajapakse N; Klee EW; Church JA; Williams A; Wong M; Burkhart C; Uzel G; Croucher DR; James DE; Ma CS; Brink R; Tangye SG; Deenick EK
J Exp Med; 2023 Jun; 220(6):. PubMed ID: 36943234
[TBL] [Abstract][Full Text] [Related]
34. Modulating the PI3K Signalling Pathway in Activated PI3K Delta Syndrome: a Clinical Perspective.
Berglund LJ
J Clin Immunol; 2023 Dec; 44(1):34. PubMed ID: 38148368
[TBL] [Abstract][Full Text] [Related]
35. Immunodeficiency due to a novel variant in PIK3CD: a case report.
Shashaani N; Chavoshzadeh Z; Ghasemi L; Ghotbabadi SH; Shiari S; Sharafian S; Shiari R
Pediatr Rheumatol Online J; 2023 Jul; 21(1):71. PubMed ID: 37475052
[TBL] [Abstract][Full Text] [Related]
36. Systematic review of mortality and survival rates for APDS.
Hanson J; Bonnen PE
Clin Exp Med; 2024 Jan; 24(1):17. PubMed ID: 38280023
[TBL] [Abstract][Full Text] [Related]
37. Thyroid Carcinoma in a Child with Activated Phosphoinositide 3-Kinase δ Syndrome: Somatic Effect of a Germline Mutation.
Bucciol G; Willems L; Hauben E; Uyttebroeck A; Proesmans M; Meyts I
J Clin Immunol; 2017 Jul; 37(5):422-426. PubMed ID: 28601916
[No Abstract] [Full Text] [Related]
38. PI3K pathway defects leading to immunodeficiency and immune dysregulation.
Nunes-Santos CJ; Uzel G; Rosenzweig SD
J Allergy Clin Immunol; 2019 May; 143(5):1676-1687. PubMed ID: 31060715
[TBL] [Abstract][Full Text] [Related]
39. Paternal gonadal mosaicism as cause of a puzzling inheritance pattern of activated PI3-kinase delta syndrome.
Segundo GRS; Takano OA; Moraes LSL; Nadaf MISV; Fernandes SJ; Ochs HD; Torgerson TR
Ann Allergy Asthma Immunol; 2017 Dec; 119(6):564-566. PubMed ID: 29107464
[No Abstract] [Full Text] [Related]
40. Herpesviruses in the Activated Phosphatidylinositol-3-Kinase-δ Syndrome.
Cohen JI
Front Immunol; 2018; 9():237. PubMed ID: 29599765
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
